Scarica l'app Stockscreener
2.4104
1.47%
-0.0396
Precedente Chiudi:
$2.45
Aprire:
$2.45
Volume 24 ore:
428.85K
Relative Volume:
0.30
Capitalizzazione di mercato:
$238.39M
Reddito:
$58.36M
Utile/perdita netta:
$-25.72M
Rapporto P/E:
-6.6202
EPS:
-0.3641
Flusso di cassa netto:
$-24.91M
1 W Prestazione:
+5.41%
1M Prestazione:
-3.83%
6M Prestazione:
-49.02%
1 anno Prestazione:
-24.33%
Intervallo 1D:
$2.39
$2.48
Intervallo di 1 settimana:
$2.145
$2.555
Portata 52W:
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Nome
Aquestive Therapeutics Inc
Settore
Telefono
908-941-1900
Indirizzo
30 TECHNOLOGY DRIVE, WARREN, NJ
Confronta AQST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
2.40 | 283.08M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
HLN
Haleon Plc Adr
|
10.96 | 48.25B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.62 | 72.09B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.88 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.20 | 44.32B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.86 | 20.60B | 16.54B | -1.64B | 749.00M | -1.45 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2019-04-22 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-03 | Iniziato | Lake Street | Buy |
| 2018-08-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-08-20 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts - Defense World
Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst - Defense World
AQST FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for AQST Issued By Leerink Partnrs - Defense World
HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Aquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerate - MSN
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results - simplywall.st
Aquestive Therapeutics’ Earnings Call: Mixed Outlook - TipRanks
AQST: Aquestive Therapeutics Receives Continued "Buy" Rating from HC Wainwright | AQST Stock News - GuruFocus
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2025 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm - TipRanks
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% By Investing.com - Investing.com Nigeria
AQST Price Target Reduced by Piper Sandler | AQST Stock News - GuruFocus
Aquestive (AQST) Reports Lower Q1 Revenue, Focuses on Anaphylm L - GuruFocus
Aquestive Therapeutics (AQST) Anticipates FDA Milestone for Anap - GuruFocus
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7% - Investing.com
Aquestive Therapeutics Inc Reports Q1 2025 EPS of -$0.24, Missin - GuruFocus
Aquestive Therapeutics: Q1 Earnings Snapshot - The Washington Post
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Reports Q1 2025 Result - GuruFocus
Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials - Investing.com Australia
Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c) - TipRanks
Aquestive Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aquestive Therapeutics Submits NDA for Anaphylm - TipRanks
Aquestive Therapeutics, Inc. SEC 10-Q Report - TradingView
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday - Defense World
Aquestive Therapeutics (AQST) Q1 Earnings Preview: Expectations and Revisions - GuruFocus
Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Raymond James Financial Inc. Acquires New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Wells Fargo & Company MN - Defense World
Aquestive Therapeutics at Citizens JMP: Strategic Moves in Allergy Treatment - Investing.com Australia
Quarterly Metrics: Quick and Current Ratios for Aquestive Therapeutics Inc (AQST) - DWinneX
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference - The Manila Times
Aquestive Therapeutics CEO Fireside Chat: Key Updates Coming at Citizens Life Sciences Conference - Stock Titan
Renaissance Technologies LLC Boosts Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential - Seeking Alpha
JPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Inc (AQST) deserves deeper analysis - uspostnews.com
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics Inc (AQST) receives an Overweight rating from Cantor Fitzgerald - knoxdaily.com
Aquestive Therapeutics Inc’s Market Journey: Closing Weak at 2.83, Down -1.39 - DWinneX
Anaphylaxis Treatment Market Size in 7MM is expected to grow at - openPR.com
Aquestive Therapeutics Inc Azioni (AQST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.03%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):